Success Metrics

Clinical Success Rate
91.5%

Based on 503 completed trials

Completion Rate
91%(503/550)
Active Trials
49(7%)
Results Posted
30%(152 trials)
Terminated
47(7%)

Phase Distribution

Ph not_applicable
105
15%
Ph phase_3
54
8%
Ph phase_1
327
46%
Ph phase_2
53
7%
Ph phase_4
150
21%
Ph early_phase_1
11
2%

Phase Distribution

338

Early Stage

53

Mid Stage

204

Late Stage

Phase Distribution700 total trials
Early Phase 1First-in-human
11(1.6%)
Phase 1Safety & dosage
327(46.7%)
Phase 2Efficacy & side effects
53(7.6%)
Phase 3Large-scale testing
54(7.7%)
Phase 4Post-market surveillance
150(21.4%)
N/ANon-phased studies
105(15.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.9%

503 of 572 finished

Non-Completion Rate

12.1%

69 ended early

Currently Active

49

trials recruiting

Total Trials

715

all time

Status Distribution
Active(67)
Completed(503)
Terminated(69)
Other(76)

Detailed Status

Completed503
unknown75
Terminated47
Recruiting35
Withdrawn22
Not yet recruiting16

Development Timeline

Analytics

Development Status

Total Trials
715
Active
49
Success Rate
91.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 111 (1.6%)
Phase 1327 (46.7%)
Phase 253 (7.6%)
Phase 354 (7.7%)
Phase 4150 (21.4%)
N/A105 (15.0%)

Trials by Status

completed50370%
unknown7510%
withdrawn223%
active_not_recruiting142%
suspended10%
recruiting355%
not_yet_recruiting162%
enrolling_by_invitation20%
terminated477%

Recent Activity

Clinical Trials (715)

Showing 20 of 715 trialsScroll for more
NCT02783040Phase 1

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Completed
NCT06154447Phase 1

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Recruiting
NCT07525544Phase 1

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

Not Yet Recruiting
NCT07227454Phase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Recruiting
NCT02365597Phase 2

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Active Not Recruiting
NCT07340190Phase 1

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Not Yet Recruiting
NCT05505630Early Phase 1

The Effects of Sedatives on Tobacco Use Disorder Version 2

Completed
NCT05258110Phase 1

A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

Completed
NCT06679413Phase 1

A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants

Completed
NCT06964776Phase 1

A Study of LY4268989 (MORF-057) in Healthy Participants

Completed
NCT05355701Phase 1

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Recruiting
NCT07435194Phase 1

A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

Recruiting
NCT05378100Phase 2

Ketamine for Multiple Sclerosis Fatigue

Active Not Recruiting
NCT07184801Phase 3

Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy

Recruiting
NCT06716190Phase 1

A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People

Terminated
NCT03600883Phase 1

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Active Not Recruiting
NCT06564441Phase 1

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Completed
NCT07426757Phase 1

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Not Yet Recruiting
NCT07443254Phase 1

Prospective IR-led Sedation Feasibility

Recruiting
NCT07118215Phase 1

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
715